Caris Life Sciences is a patient-centric, next-generation AI TechBio company and precision medicine pioneer that develops and commercializes innovative solutions through comprehensive molecular profiling and advanced AI and machine learning algorithms. The company provides comprehensive molecular profiling services analyzing DNA, RNA, and proteins to understand cancer at the molecular level, including MI Profile (whole exome and transcriptome sequencing for 23,000+ genes), Caris Assure (blood-based diagnostics), and AI-driven molecular tumor board reports. Caris has built one of the largest multimodal databases of combined molecular and clinical outcomes data with more than 740,000 matched patient records.
Caris Life Sciences is publicly traded
IPO'd on Jun 20, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under CAI.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
1,468–1,700
Total Funding
$2.35B
7 rounds
Last Private Valuation
$5.95B
Jun 18, 2025
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $2.35B across 7 rounds
Last updated 08-21-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Jun 18, 2025 | IPO | $494M | $5.95B | Not disclosed |
| Apr 7, 2025 | Pre-IPO growth equity Press release | $168M | — | Braidwell LP |
| Jan 19, 2023 | Senior secured debt Press release | $400M | — | OrbiMed, Braidwell |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series D (growth equity)
$7.8B
May 2021
Caris Life Sciences today
$6.0B
Jun 2025 · latest mark
Caris Life Sciences multiple
0.8x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
David Dean Halbert
Founder, Chairman & CEO
Yes, Caris Life Sciences is publicly traded under the ticker symbol CAI on the NASDAQ. The company went public in Jun 20, 2025.
Caris Life Sciences trades under the ticker symbol CAI on the NASDAQ. It began trading in Jun 20, 2025.
Caris Life Sciences (CAI on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CAI to place an order.
Caris Life Sciences went public in Jun 20, 2025 via ipo, with an offering valuation of approximately $5.95B. Caris Life Sciences completed its initial public offering on June 20, 2025, listing on the Nasdaq Global Select Market under ticker symbol CAI. The company priced 23,529,412 shares at $21.00 per share, raising $494.1 million. Shares began trading June 18, 2025, and surged 33% on the first day of trading. The company achieved a market valuation of $7.9 billion at IPO.
Caris Life Sciences raised $2.35B across 7 disclosed funding rounds prior to its public listing.
Caris Life Sciences was founded by David Dean Halbert in 2008.
Caris Life Sciences is headquartered in Irving, Texas, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.